Table 2. HRs of clinical characteristics of patients with B-cell lymphoma treated by R-CHOP for overall survival and progression-free survival (n = 90).
HR, hazard ratio; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; CI, confidence interval; IPI, International Prognostic Index.